Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: principles (564), values (295)

DVd_Twice weekly_Daratumumab-Bortezomib-Dexamethasone_Cycles 1 to 8

Description: Chemotherapy Protocol Myeloma DVd (twice weekly) Bortezomib-Daratumumab-Dexamethasone (cycles 1 to 8) Regimen • Myeloma – Bortezomib (twice weekly)-Daratumumab-Dexamethasone Indication
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVd-Twice-weekly-Daratumumab-Bortezomib-Dexamethasone-Cycles-1-to-8.pdf

DVd Weekly Daratumumab-Bortezomib-Dexamethasone Cycles 1 to 8

Description: Chemotherapy Protocol Myeloma DVd (Weekly) Bortezomib-Daratumumab-Dexamethasone (cycles 1 to 8) Regimen • Myeloma – Bortezomib (weekly)-Daratumumab-Dexamethasone Indication • Daratumumab in
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVd-Weekly-Daratumumab-Bortezomib-Dexamethasone-Cycles-1-to-8.pdf

ObinutuzumabVenetoclax LowRisk

Description: Chemotherapy Protocol Chronic Lymphocytic Leukaemia Obinutuzumab-Venetoclax (Low Risk) Regimen • CLL – Obinutuzumab-Venetoclax (Low R
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/ObinutuzumabVenetoclax-LowRisk.pdf

MP000 028 Cellular pathology user handbook v24

Description: University Hospital Southampton NHS Foundation Trust PATHOLOGY DIRECTORATE Cellular Pathology (Management) MP 000 028 Revision 2
Url: /Media/UHS-website-2019/Docs/Services/Pathology/Cell-path/MP000-028-Cellular-pathology-user-handbook-v24.pdf

BRC Research Theme Lead Designate JD and PS

Description: NIHR Southampton Biomedical Research Centre Research Theme Lead Designate National Institute for Health and Care Research (NIHR) Biomedical Re
Url: /Media/Southampton-Clinical-Research/Downloads/BRC-Research-Theme-Lead-Designate-JD-and-PS.docx

RIPCORD Privacy Notice UHS v7_12th August 2025

Description: This is a PRIVACY NOTICE for patients who took part in the RIPCORD 2 study Chief Investigator: Professor Nicholas Curzen, University Hospital
Url: /Media/Southampton-Clinical-Research/Downloads/RIPCORD-Privacy-Notice-UHS-v7-12th-August-2025.pdf

Papers CoG 28.10.2025

Description: Date Time Location Chair Agenda - Council of Governors 28/10/2025 14:00 - 15:30 Heartbeat Conference Room/Microsoft Teams Jenni
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Governors/Papers-CoG-28.10.2025.pdf

Papers CoG 16.07.2025

Description: Date Time Location Chair Agenda Council of Governors 16/07/2025 14:00 - 15:30 Conference Room, Heartbeat/Microsoft Teams Jenni Douglas-Tod
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Governors/Papers-CoG-16.07.2025.pdf

Sunitinib v1.1

Description: Regimen Renal Cell - Sunitinib Indication Chemotherapy Protocol RENAL CELL SUNITINIB First line treatment of advanced or metastatic renal cell carcinoma WHO
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Sunitinib-v1.1.pdf

Pazopanib v1.1

Description: Chemotherapy Protocol RENAL CELL PAZOPANIB Regimen Renal Cell - Pazopanib Indication First line treatment option for people with advanced renal cell carcinoma
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Pazopanib-v1.1.pdf

161 to 170 of 427

Previous … 15 16 17 18 19 … Next